IL-1 binding proteins
First Claim
Patent Images
1. A method for reducing human IL-1 activity in a human subject in need thereof, comprising administering to the human subject a binding protein, wherein the binding protein comprises first and second polypeptide chains, wherein said first polypeptide chain comprises a first VD1-(X1)n-VD2-C-(X2)n, wherein:
- VD1 is a first heavy chain variable domain;
VD2 is a second heavy chain variable domain;
C is a heavy chain constant domain;
X1 is a linker with the proviso that it is not CH1;
X2 is an Fc region; and
n is independently 0 or 1; and
wherein said second polypeptide chain comprises a second VD1-(X1)n-VD2-C-(X2)n,wherein;
VD1 is a first light chain variable domain;
VD2 is a second light chain variable domain;
C is a light chain constant domain;
X1 is a linker with the proviso that it is not CH1;
X2 does not comprise an Fc region; and
n is independently 0 or 1;
wherein, in said first polypeptide chain, VD1 comprises the amino acid sequence of SEQ ID NO;
204; and
VD2 comprises the amino acid sequence of SEQ ID NO;
213;
wherein, in said second polypeptide chain, VD1 comprises the amino acid sequence of SEQ ID NO;
238; and
VD2 comprises the amino acid sequence of SEQ ID NO;
216; and
wherein the binding protein binds human IL-1β and
human IL-la, such that the human IL-1 activity in the human subject is reduced.
2 Assignments
0 Petitions
Accused Products
Abstract
Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.
-
Citations
18 Claims
-
1. A method for reducing human IL-1 activity in a human subject in need thereof, comprising administering to the human subject a binding protein, wherein the binding protein comprises first and second polypeptide chains, wherein said first polypeptide chain comprises a first VD1-(X1)n-VD2-C-(X2)n, wherein:
-
VD1 is a first heavy chain variable domain; VD2 is a second heavy chain variable domain; C is a heavy chain constant domain; X1 is a linker with the proviso that it is not CH1; X2 is an Fc region; and n is independently 0 or 1; and wherein said second polypeptide chain comprises a second VD1-(X1)n-VD2-C-(X2)n, wherein; VD1 is a first light chain variable domain; VD2 is a second light chain variable domain; C is a light chain constant domain; X1 is a linker with the proviso that it is not CH1; X2 does not comprise an Fc region; and n is independently 0 or 1; wherein, in said first polypeptide chain, VD1 comprises the amino acid sequence of SEQ ID NO;
204; and
VD2 comprises the amino acid sequence of SEQ ID NO;
213;wherein, in said second polypeptide chain, VD1 comprises the amino acid sequence of SEQ ID NO;
238; and
VD2 comprises the amino acid sequence of SEQ ID NO;
216; andwherein the binding protein binds human IL-1β and
human IL-la, such that the human IL-1 activity in the human subject is reduced. - View Dependent Claims (2, 3, 4, 5, 6, 13, 14, 15, 16, 18)
-
-
7. A method for reducing human IL-1 activity in a human subject in need thereof, comprising administering to the human subject a binding protein, wherein the binding protein comprises first and second polypeptide chains, wherein said first polypeptide chain comprises a first VD1-(X1)n-VD2-C-(X2)n, wherein:
-
VD1 is a first heavy chain variable domain; VD2 is a second heavy chain variable domain; C is a heavy chain constant domain; X1 is a linker with the proviso that it is not CH1; X2 is an Fc region; and n is independently 0 or 1; and wherein said second polypeptide chain comprises a second VD1-(X1)n-VD2-C-(X2)n, wherein; VD1 is a first light chain variable domain; VD2 is a second light chain variable domain; C is a light chain constant domain; X1 is a linker with the proviso that it is not CH1; X2 does not comprise an Fc region; and n is independently 0 or 1; wherein said first polypeptide chain comprises the amino acid sequence of SEQ ID NO;
212;
wherein said second polypeptide chain comprises the amino acid sequence of SEQ ID NO;
215; andwherein the binding protein binds human IL-1β and
human IL-la, such that the human IL-1 activity is reduced. - View Dependent Claims (8, 9, 10, 11, 12, 17)
-
Specification